Hamel Lauren M, Penner Louis A, Albrecht Terrance L, Heath Elisabeth, Gwede Clement K, Eggly Susan
Wayne State University, Karmanos Cancer Institute, Department of Oncology, Population Studies Disparities Research Program, Detroit, MI, USA.
Cancer Control. 2016 Oct;23(4):327-337. doi: 10.1177/107327481602300404.
Clinical trials that study cancer are essential for testing the safety and effectiveness of promising treatments, but most people with cancer never enroll in a clinical trial - a challenge exemplified in racial and ethnic minorities. Underenrollment of racial and ethnic minorities reduces the generalizability of research findings and represents a disparity in access to high-quality health care.
Using a multilevel model as a framework, potential barriers to trial enrollment of racial and ethnic minorities were identified at system, individual, and interpersonal levels. Exactly how each level directly or indirectly contributes to doctor-patient communication was also reviewed. Selected examples of implemented interventions are included to help address these barriers. We then propose our own evidence-based intervention addressing barriers at the individual and interpersonal levels.
Barriers to enrolling a diverse population of patients in clinical trials are complex and multilevel. Interventions focused at each level have been relatively successful, but multilevel interventions have the greatest potential for success.
To increase the enrollment of racial and ethnic minorities in clinical trials, future interventions should address barriers at multiple levels.
研究癌症的临床试验对于测试有前景的治疗方法的安全性和有效性至关重要,但大多数癌症患者从未参加过临床试验——这一挑战在少数种族和族裔群体中尤为明显。少数种族和族裔群体参与率低降低了研究结果的普遍性,也体现了获得高质量医疗保健方面的差异。
以多层次模型为框架,在系统、个体和人际层面确定少数种族和族裔群体参与试验的潜在障碍。还回顾了每个层面如何直接或间接影响医患沟通。文中包含了已实施干预措施的选定示例,以帮助克服这些障碍。然后,我们提出了自己基于证据的干预措施,以解决个体和人际层面的障碍。
让不同患者群体参与临床试验的障碍是复杂且多层次的。针对每个层面的干预措施相对成功,但多层次干预措施取得成功的潜力最大。
为了提高少数种族和族裔群体参与临床试验的比例,未来的干预措施应解决多个层面的障碍。